Health & bio

FDA approves Eli Lilly oral GLP-1 'Foundayo' for obesity April 1

FDA cleared orforglipron (Foundayo) on April 1, shipping via LillyDirect starting April 6. Lowest-dose patient cash price: $149 monthly, matching Novo Nordisk's Wegovy.

Primary sources · 2
Detroit NewsBioPharma Dive
← View the full 2026-04-01 (Wed) issue
What you're reading now arrives in your inbox daily at 21:00 UTC.

Get today's brief every day at 21:00 UTC

7 must-reads · 17 fields · tracked storylines delivered to your inbox daily. Pick only the fields you want; unsubscribe anytime.

Past issues →